Sadaf Ghaem‐Maghami

ORCID: 0000-0002-7369-5080 · 14 papers in corpus
2025
Cancers ·doi:10.3390/cancers17233825

Background/Objectives: To determine whether long-term oncological follow-up is required following fertility-sparing surgery (FSS) for mucinous borderline ovarian tumours (MBOTs). Methods: A retrospective cohort study set in the tertiary gyn…

preprint 2023
·doi:10.1158/0008-5472.c.6500271.v1

AbstractEndometrial cancer is the most common malignancy of the lower female reproductive tract. The tumor suppressor FOXO1 is downregulated in endometrial cancer compared with normal endometrium but the underlying mechanisms are not well u…

preprint 2023
·doi:10.1158/0008-5472.22382649.v1

Supplementary Figure 1 from Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

preprint 2023
·doi:10.1158/0008-5472.22382649

Supplementary Figure 1 from Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

preprint 2023
·doi:10.1158/0008-5472.22382646.v1

Supplementary Figure 2 from Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

preprint 2023
·doi:10.1158/0008-5472.22382646

Supplementary Figure 2 from Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

preprint 2023
·doi:10.1158/0008-5472.22382643

Supplementary Figure Legends 1-2 from Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

preprint 2023
·doi:10.1158/0008-5472.22382643.v1

Supplementary Figure Legends 1-2 from Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

article 2022
BMJ open ·doi:10.1136/bmjopen-2021-060409

INTRODUCTION: The lifetime risk of women undergoing surgery for the presence of benign ovarian pathology in the UK is 5%-10%. Despite minimally invasive surgical techniques, evidence suggests a number of healthy ovarian follicles and tissue…

article 2019
·doi:10.1007/s00404-019-05306-6

PURPOSE: Uterine adenosarcomas (UAs) account for 5-8% of cases of uterine sarcomas. Treatment includes total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO). Fertility preservation is an emerging concept in gynaecolog…

2016
Scientific reports ·doi:10.1038/srep39219

Ovarian cancer is highly prevalent among European women, and is the leading cause of gynaecological cancer death. Current histopathological diagnoses of tumour severity are based on interpretation of, for example, immunohistochemical staini…

2013
The oncologist ·doi:10.1634/theoncologist.2012-0416

BackgroundAn association between treatment for gynecological cancers and risk of osteoporosis has never been formally evaluated. Women treated for these cancers are now living longer than ever before, and prevention of treatment-induced mor…

2010
Cancer research ·doi:10.1158/0008-5472.can-09-1891

Endometrial cancer is the most common malignancy of the lower female reproductive tract. The tumor suppressor FOXO1 is downregulated in endometrial cancer compared with normal endometrium but the underlying mechanisms are not well understoo…

article 2010
The American Journal of Pathology ·doi:10.2353/ajpath.2010.090325

Local estrogen production plays a key role in proliferative endometrial disorders, such as endometrial hyperplasia and cancer. Hydroxysteroid (17beta) dehydrogenase 1 (HSD17B1) is an enzyme that catalyzes with high efficiency the conversion…